News
16h
Zacks Investment Research on MSNIs Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...
Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...
The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...
1h
Asianet Newsable on MSNHims & Hers Announces Plans To Expand Into Canada As Novo Nordisk’s Weight Loss Drug Patent ExpiresThe telehealth company stated that its entry to Canada will come as generic Semaglutide hits the market for the first time.
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...
Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...
Citing “unprecedented demand,” drugmaker Novo Nordisk said Thursday it expects supply restrictions on starter doses of the weight loss medicine Wegovy to persist into 2024, several months ...
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...
Novo Nordisk is already struggling to keep pace with runaway demand for Wegovy, which clinical trials have shown can help people lose 15% of their body weight after less than 16 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results